283
Participants
Start Date
February 2, 2012
Primary Completion Date
April 22, 2016
Study Completion Date
April 22, 2016
DVS SR
Subjects will receive a flexible-dose of 20, 25, 35, or 50 mg/day as prescribed by the investigator
Bioscience Research, LLC., Mount Kisco
The Zucker Hillside Hospital, North Shore-Long Island Jewish Health System, Glen Oaks
Erie County Medical Center/State University of New York (SUNY) at Buffalo Affiliate, Buffalo
Finger Lakes Clinical Research, Rochester
Pharmasite Research, Inc, Baltimore
Allance Research Group, Richmond
Alliance Research Group, Richmond
Virginia Commonwealth University, Richmond
Virginia Treatment Center for Children, Richmond
Northwest Behavioral Research Center, Marietta
Clinical Neuroscience Solutions, Jacksonville
SJS Clinical Research, Inc., Destin
Sarkis Clinical Trials, Gainesville
Medical Research Group of Central Florida, Orange City
Millenia Psychiatry & Research, Inc., Orlando
Janus Center for Psychiatric Research, West Palm Beach
Research Strategies of Memphis, LLC., Memphis
Discovery and Wellness Center for Children/University Hospitals Case Medical Center, Cleveland
Neuro-Behavioral Clinical Research, Inc., Canton
Clinco, Terre Haute
Capstone Clinical Research, Libertyville
Baber Research Group, Naperville
Millennium Psychiatric Associates, LLC, Creve Coeur
Premier Psychiatric Research Institute, LLC, Lincoln
Sooner Clinical Research, Oklahoma City
Clinical Trials of Texas, Inc., San Antonio
Clinical Trials of Texas, INC, San Antonio
FutureSearch Trials, Austin
MCB Clinical Research Centers, Colorado Springs
Center for Advanced Improvement, Tucson
Sun Valley Research Center, Imperial
Eastside Therapeutic Resource, Kirkland
Biomedica Research Group, Santiago
The University Of Alabama At Birmingham, Office Of Psychiatric Research, Birmingham
Institute of Living/Hartford Hospital, Hartford
Stony Brook University Medical Center, child and Adolescent Psychiatry, Stony Brook
Lead Sponsor
Pfizer
INDUSTRY